​

ACADIA Pharmaceuticals (ACAD) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ACAD Stock Forecast

ACADIA Pharmaceuticals (ACAD) stock forecast, based on 18 Wall Street analysts, predicts a 12-month average price target of $20.00, with a high of $20.00 and a low of $20.00. This represents a 8.87% increase from the last price of $18.37.

$10 $15 $20 $25 $30 $35 High: $20 Avg: $20 Low: $20 Last Closed Price: $18.37

ACAD Stock Rating

ACADIA Pharmaceuticals stock's rating consensus is Buy, based on 18 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (61.11%), 6 Hold (33.33%), 1 Sell (5.56%), and 0 Strong Sell (0.00%).

Buy
Total 18 1 6 11 0 Strong Sell Sell Hold Buy Strong Buy

ACAD Forecast vs Benchmarks

TypeNameUpside
StockACADIA Pharmaceuticals8.87%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts1112
Avg Price Target$20.00$20.00$27.50
Last Closing Price$18.37$18.37$18.37
Upside/Downside8.87%8.87%49.70%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 25676-120
Dec, 24676-120
Nov, 24676-120
Oct, 2461061124
Sep, 2461051123
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 03, 2025Yatin SunejaGuggenheim$20.00$18.498.17%8.87%
Aug 07, 2024Jeffrey HungMorgan Stanley$20.00$18.856.10%8.87%
Jun 26, 2024Keith TapperBMO Capital$31.00$15.50100.00%68.75%
May 09, 2024Andrew FeinH.C. Wainwright$27.00$17.1357.62%46.98%
May 09, 2024Joel BeattyRobert W. Baird$28.00$17.1363.46%52.42%
May 09, 2024Uy EarMizuho Securities$21.00$17.1322.59%14.32%
Apr 30, 2024Ashwani VermaUBS$27.00$17.1057.89%46.98%
Mar 12, 2024Ashwani VermaUBS$33.00$19.9865.17%79.64%
Mar 12, 2024Jay OlsonOppenheimer$19.00$19.98-4.90%3.43%
Mar 12, 2024Ami FadiaNeedham$32.00$19.9860.16%74.20%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Jan 03, 2025GuggenheimBuyNeutraldowngrade
Oct 17, 2024GuggenheimBuyBuyhold
Oct 10, 2024UBSBuyBuyhold
Aug 07, 2024RBC CapitalEqual-WeightEqual-Weighthold
Aug 07, 2024Morgan StanleyOverweightEqual-Weightdowngrade
Jun 26, 2024BMO CapitalBuyOutperforminitialise
Jun 25, 2024RBC CapitalBuyBuyhold
May 09, 2024H.C. WainwrightBuyBuyhold
Apr 30, 2024RBC CapitalBuyBuyhold
Apr 30, 2024UBSBuyBuyhold

Financial Forecast

EPS Forecast

$-2 $-1 $0 $1 $2 $3 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.79$-1.05$-1.34$-0.37-----
Avg Forecast$-1.84$-1.02$-1.32$-0.36$0.72$0.75$1.12$1.67$2.18
High Forecast$-1.94$-1.08$-1.42$-0.47$0.43$0.24$0.43$0.11$2.07
Low Forecast$-1.70$-0.94$-1.25$-0.07$1.21$1.19$2.27$2.78$2.32
Surprise %-2.72%2.94%1.52%2.78%-----

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$441.75M$484.14M$517.24M$726.44M-----
Avg Forecast$443.75M$487.98M$514.79M$719.17M$969.65M$1.05B$1.17B$1.30B$1.44B
High Forecast$417.17M$458.75M$496.61M$709.72M$964.06M$1.02B$1.17B$1.29B$1.39B
Low Forecast$462.99M$509.14M$546.26M$723.91M$975.90M$1.09B$1.18B$1.31B$1.51B
Surprise %-0.45%-0.79%0.47%1.01%-----

Net Income Forecast

$-350M $-180M $-10M $160M $330M $500M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-281.58M$-167.87M$-215.97M$-61.29M-----
Avg Forecast$-257.72M$-187.72M$-252.14M$-61.29M$128.51M$134.26M$208.81M$282.56M$357.29M
High Forecast$-309.26M$-225.27M$-302.57M$-73.54M$70.93M$38.68M$71.02M$18.15M$339.05M
Low Forecast$-206.17M$-150.18M$-201.71M$-49.03M$197.58M$194.99M$371.62M$455.51M$379.72M
Surprise %9.26%-10.58%-14.34%------

ACAD Forecast FAQ

Is ACADIA Pharmaceuticals stock a buy?

ACADIA Pharmaceuticals stock has a consensus rating of Buy, based on 18 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 6 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that ACADIA Pharmaceuticals is a favorable investment for most analysts.

What is ACADIA Pharmaceuticals's price target?

ACADIA Pharmaceuticals's price target, set by 18 Wall Street analysts, averages $20 over the next 12 months. The price target range spans from $20 at the low end to $20 at the high end, suggesting a potential 8.87% change from the previous close price of $18.37.

How does ACADIA Pharmaceuticals stock forecast compare to the average forecast of its sector, industry, and investment themes?

ACADIA Pharmaceuticals stock forecast shows a 8.87% upside, underperforming the average forecast for the healthcare stocks sector (25.20%) and underperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for ACADIA Pharmaceuticals over the past three months?

  • January 2025: 30.00% Strong Buy, 35.00% Buy, 30.00% Hold, 0% Sell, 5.00% Strong Sell.
  • December 2024: 30.00% Strong Buy, 35.00% Buy, 30.00% Hold, 0% Sell, 5.00% Strong Sell.
  • November 2024: 30.00% Strong Buy, 35.00% Buy, 30.00% Hold, 0% Sell, 5.00% Strong Sell.

What is ACADIA Pharmaceuticals’s EPS forecast?

ACADIA Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December is 0.72 for 2024, a -294.59% decrease from the reported $-0.37 in 2023. The prediction for 2025 is $0.75, $1.12 for 2026, $1.67 for 2027, and $2.18 for 2028.

What is ACADIA Pharmaceuticals’s revenue forecast?

ACADIA Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December is $969.65M for 2024, a 33.48% increase from the reported $726.44M in 2023. The forecast for 2025 is $1.05B, $1.17B for 2026, $1.3B for 2027, and $1.44B for 2028.

What is ACADIA Pharmaceuticals’s net income forecast?

For its fiscal year ending in December, ACADIA Pharmaceuticals's average annual net income forecast is $128.51M for 2024, reflecting a -309.68% decrease from the reported $-61.286M in 2023. The projection for 2025 is $134.26M, $208.81M for 2026, $282.56M for 2027, and $357.29M for 2028.